id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9678 R34454 |
Tomson (Carbamazepine), 2018 | Polydactyly | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 6.43 [0.31;134.02] C | 2/1,957 0/2,514 | 2 | 1,957 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9625 R34229 |
Källén (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 | Poly/syndactyly | early pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.20 [0.29;5.02] C excluded (control group) |
5/1,511 3/1,084 | 8 | 1,511 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9626 R34237 |
Källén (Carbamazepine) (Controls unexposed, NOS) (Indications NOS), 2013 | Poly/syndactyly | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.45 [0.47;3.38] | 5/1,511 3,084/1,575,847 | 3,089 | 1,511 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9653 R34362 |
Bànhidy (Carbamazepine), 2011 | Poly/syndactyly | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 0.30 [0.01;8.33] C | 0/10 2/12 | 2 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9648 R34334 |
Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 | Polydactyly | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.19 [0.09;54.89] C | 1/72 0/52 | 1 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9612 R34088 |
D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 | Extra digits | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
123.00 [3.40;4444.20] C excluded (control group) |
1/3 0/62 | 1 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9613 R34117 |
D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 | Extra digits | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 15.00 [0.39;576.73] C | 1/3 0/8 | 1 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 1.71 [0.74;3.99] | 3,095 | 3,553 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine; 2: Carbamazepine) (Controls unexposed, NOS) (Indications NOS; 3: Carbamazepine; 4: Carbamazepine) (Controls unexposed, sick) ; 5: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.5380 (by Egger's regression)
slope=0.0848 (0.7774); intercept=0.5586 (0.8058); t=0.6932; p=0.5380
excluded 9612, 9625